Clinical Trial Update: Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating intratumor LMB-100 with ipilimumab in mesothelioma; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Mesothelioma

Drugs mentioned

• LMB-100 (mesothelin-targeted immunotoxin)
• ipilimumab (ipilimumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Mesothelioma | Phase 1 | Status: TERMINATED | Results posted: 2024-02-02